Recurrent WWTR1 S89W mutations and Hippo pathway deregulation in clear cell carcinomas of the cervix
暂无分享,去创建一个
S. Chandarlapaty | J. Reis-Filho | B. Weigelt | R. Murali | J. R. Lapa e Silva | Kay J. Park | R. Bi | N. Abu-Rustum | H. Dopeso | D. Zamarin | P. Selenica | F. Pareja | Ju-Yoon Yoon | A. Maroldi | Cathleen E. Matrai | Qing Li | E. D. da Silva | Thais Basili | Sarah H. Kim | Etta Hanlon | A. Da Cruz Paula | Shirin Issa Bhaloo | Yingjie Zhu | T. Hoang | E. Chan | Michelle Wu | F. Derakhshan | C. G. Ferreira | C. Ferreira | Etta J Hanlon | Higinio Dopeso | Eric Chan
[1] Jonghwan Kim,et al. Context-dependent roles of YAP/TAZ in stem cell fates and cancer , 2021, Cellular and Molecular Life Sciences.
[2] D. Bowtell,et al. Noncanonical IL6 Signaling-Mediated Activation of YAP Regulates Cell Migration and Invasion in Ovarian Clear Cell Cancer , 2020, Cancer Research.
[3] A. Zaravinos,et al. Human papillomavirus E7 binds Oct4 and regulates its activity in HPV-associated cervical cancers , 2020, PLoS pathogens.
[4] O. Peralta-Zaragoza,et al. MiR-23b-3p reduces the proliferation, migration and invasion of cervical cancer cell lines via the reduction of c-Met expression , 2020, Scientific Reports.
[5] J. Reis-Filho,et al. Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary , 2020, Nature Communications.
[6] Kay J. Park. Cervical adenocarcinoma: integration of HPV status, pattern of invasion, morphology and molecular markers into classification , 2019, Histopathology.
[7] C. G. Hansen,et al. The Hippo Pathway, YAP/TAZ, and the Plasma Membrane. , 2019, Trends in cell biology.
[8] Corrigendum to “Revised FIGO staging for carcinoma of the cervix uteri” [Int J Gynecol Obstet 145(2019) 129–135] , 2019, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[9] O. Mariani,et al. The Genomic Landscape of Mucinous Breast Cancer. , 2019, Journal of the National Cancer Institute.
[10] I. Petersen,et al. SCLEROSING EPITHELIOID MESENCHYMAL NEOPLASM OF THE PANCREAS A PROPOSED NEW ENTITY , 2019, Modern Pathology.
[11] R. Soslow,et al. Recent advances in invasive adenocarcinoma of the cervix , 2019, Virchows Archiv.
[12] W. Hong,et al. Role of Hippo Pathway-YAP/TAZ Signaling in Angiogenesis , 2019, Front. Cell Dev. Biol..
[13] J. Berek,et al. Revised FIGO staging for carcinoma of the cervix uteri , 2019, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[14] Ronglai Shen,et al. Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. , 2018, Cancer cell.
[15] Leng Han,et al. Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer , 2018, Cell reports.
[16] I. Ellis,et al. Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors , 2018, Nature Communications.
[17] I. Ellis,et al. Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas , 2018, Nature Communications.
[18] D. Huo,et al. Follow-up of Patients with Clear-Cell Adenocarcinoma of the Vagina and Cervix. , 2018, The New England journal of medicine.
[19] Ashton C. Berger,et al. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. , 2018, Cancer cell.
[20] Steven J. M. Jones,et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. , 2018, Cell.
[21] Peter W. Laird,et al. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer , 2018, Cell.
[22] S. Bae,et al. DNA binding partners of YAP/TAZ , 2018, BMB reports.
[23] N. Socci,et al. Accelerating Discovery of Functional Mutant Alleles in Cancer. , 2018, Cancer discovery.
[24] Xiaolong Yang,et al. TAZ induces lung cancer stem cell properties and tumorigenesis by up-regulating ALDH1A1 , 2017, Oncotarget.
[25] J. Li,et al. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP‐TEAD complex , 2017, Cancer science.
[26] Shuangyue Liu,et al. LATS1 suppresses proliferation and invasion of cervical cancer , 2017, Molecular medicine reports.
[27] Steven J. M. Jones,et al. Integrated genomic and molecular characterization of cervical cancer , 2017, Nature.
[28] AACR Project GENIE: Powering Precision Medicine through an International Consortium. , 2017, Cancer discovery.
[29] Roland Eils,et al. Complex heatmaps reveal patterns and correlations in multidimensional genomic data , 2016, Bioinform..
[30] J. Shipley,et al. The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma , 2016, The Journal of pathology.
[31] V. Seshan,et al. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing , 2016, Nucleic acids research.
[32] Bin Zhao,et al. Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer , 2015, Cell.
[33] Steven J. M. Jones,et al. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer , 2015, Cell.
[34] M. Sudol,et al. TAZ Protein Accumulation Is Negatively Regulated by YAP Abundance in Mammalian Cells* , 2015, The Journal of Biological Chemistry.
[35] A. A. Stepanenko,et al. HEK293 in cell biology and cancer research: phenotype, karyotype, tumorigenicity, and stress-induced genome-phenotype evolution. , 2015, Gene.
[36] H. Nojima,et al. Homeostatic control of Hippo signaling activity revealed by an endogenous activating mutation in YAP , 2015, Genes & development.
[37] Donavan T. Cheng,et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.
[38] M. Fukayama,et al. HPV-16 impairs the subcellular distribution and levels of expression of protein phosphatase 1γ in cervical malignancy , 2015, BMC Cancer.
[39] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[40] Simion I. Chiosea,et al. Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands , 2014, Nature Genetics.
[41] T. Hasan,et al. Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer , 2014, British Journal of Cancer.
[42] Mikhail Shugay,et al. Oncofuse: a computational framework for the prediction of the oncogenic potential of gene fusions , 2013, Bioinform..
[43] Robert Gentleman,et al. Software for Computing and Annotating Genomic Ranges , 2013, PLoS Comput. Biol..
[44] G. Lou,et al. Clinical Significance of Yes-Associated Protein Overexpression in Cervical Carcinoma: The Differential Effects Based on Histotypes , 2013, International Journal of Gynecologic Cancer.
[45] Helga Thorvaldsdóttir,et al. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..
[46] Thomas R. Gingeras,et al. STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..
[47] A. McKenna,et al. Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.
[48] Bin Zhao,et al. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal , 2011, Nature Cell Biology.
[49] B. Weigelt,et al. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs , 2011, Oncogene.
[50] J. George,et al. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene , 2011, Oncogene.
[51] Nicola Elvassore,et al. Role of YAP/TAZ in mechanotransduction , 2011, Nature.
[52] A. Ashworth,et al. Genetic Interactions in Cancer Progression and Treatment , 2011, Cell.
[53] J. Reynolds,et al. Nanodrug applications in photodynamic therapy. , 2011, Photodiagnosis and photodynamic therapy.
[54] Richard A. Moore,et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. , 2010, The New England journal of medicine.
[55] E. Montgomery,et al. Expression of Yes-associated protein in common solid tumors. , 2008, Human pathology.
[56] Zhengyu Zha,et al. TAZ Promotes Cell Proliferation and Epithelial-Mesenchymal Transition and Is Inhibited by the Hippo Pathway , 2008, Molecular and Cellular Biology.
[57] Brad T. Sherman,et al. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.
[58] Li Li,et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. , 2007, Genes & development.
[59] B. Edgar,et al. Filling out the Hippo pathway , 2007, Nature Reviews Molecular Cell Biology.
[60] Jianbin Huang,et al. The Hippo Signaling Pathway Coordinately Regulates Cell Proliferation and Apoptosis by Inactivating Yorkie, the Drosophila Homolog of YAP , 2005, Cell.
[61] Jean YH Yang,et al. Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.
[62] J. Barrett,et al. Molecular genetic analysis of clear cell adenocarcinomas of the vagina and cervix associated and unassociated with diethylstilbestrol exposure in utero , 1996, Cancer.
[63] Diethylstilbestrol Contraindicated. Selected item from the FDA drug bulletin-november 1971: diethylstilbestrol contraindicated in pregnancy. , 1972, California medicine.
[64] A. Herbst,et al. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. , 1971, The New England journal of medicine.